Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 Registry

M. Gilard*, H. Eltchaninoff, P. Donzeau-Gouge, K. Chevreul, J. Fajadet, P. Leprince, A. Leguerrier, M. Lievre, A. Prat, E. Teiger, T. Lefevre, D. Tchetche, D. Carrie, D. Himbert, B. Albat, A. Cribier, A. Sudre, D. Blanchard, G. Rioufol, F. ColletR. Houel, Santos P. Dos, N. Meneveau, S. Ghostine, T. Manigold, P. Guyon, D. Grisoli, Breton H. Le, S. Delpine, R. Didier, X. Favereau, G. Souteyrand, P. Ohlmann, V. Doisy, G. Grollier, A. Gommeaux, Claudel J. -P., F. Bourlon, B. Bertrand, M. Laskar, B. Iung, M. Gilard*, M. Laskar, H. Eltchaninoff, J. Fajadet, B. Iung, E. Teiger, P. Donzeau-Gouge, P. Leprince, A. Leguerrier, A. Prat, K. Chevreul, M. Lievre, M. Bertrand, J. Cassagne, J. Boschat, J. R. Lusson, P. Mathieu, Y. Logeais, Bessou J. -P., T. Lefevre, B. Chevalier, A. Farge, P. Garot, T. Hovasse, M. C. Morice, M. Romano, P. D. Gouge, D. Tchetche, O. Vahdat, B. Farah, J. Fajadet, D. Carrie, N. Dumonteil, G. Fournial, B. Marcheix, D. Himbert, P. Nataf, A. Vahanian, B. Albat, F. Leclercq, C. Piot, L. Schmutz, P. Aubas, Cailar A. du, A. Dubar, N. Durrleman, F. Fargosz, G. Levy, E. Maupas, F. Rivalland, G. Robert, H. Eltchaninoff, Bessou J. -P., A. Cribier, C. Tron, A. Sudre, F. Juthier, T. Modine, Belle E. Van, Carlo Banfi, D. Blanchard, T. Sallerin, O. Bar, C. Barbey, S. Chassaing, D. Chatel, Page O. Le, A. Tauran, G. Rioufol, D. Cao, R. Dauphin, de Gevigney G. Durand, G. Finet, O. Jegaden, Obadia J. -F., P. Leprince, F. Beygui, Collet J. -P., A. Pavie, F. Collet, Pecheux Bayet, A. Vaillant, J. Vicat, O. Wittenberg, R. Houel, P. Joly, R. Rosario, P. Bergeron, J. Bille, R. Gelisse, E. Teiger, Couetil J. -P., Dubois Rande J. -L., D. Hayat, E. Fougeres, Monin J. -L., G. Mouillet, Santos P. Dos, F. Arsac, E. Choukroun, M. Dijos, Guibaud J. -P., L. Leroux, N. Elia, N. Meneveau, Descotes Genon, S. Chocron, F. Schiele, C. Caussin, A. Azmoun, S. Ghostine, R. Nottin, A. Tirouvanziam, D. Crochet, R. Gaudin, Roussel J. -C., P. Guyon, N. Bonnet, F. Digne, P. Mesnidrey, T. Royer, V. Stratiev, D. Grisoli, Bonnet J. -L., T. Cuisset, D. Grisoli, Breton H. Le, I. Abouliatim, M. Bedossa, D. Boulmier, J. P. Verhoye, S. Delepine, Debrux J. -L., A. Furber, F. Pinaud, M. Gilard*, E. Bezon, J. Boschat, Choplain J. -N., X. Favereau, O. Bical, G. Dambrin, P. Deleuze, A. Jegou, Lusson J. -R., K. Azarnouch, N. Durel, A. Innorta, G. Souteyrand, V. Doisy, Y. Lienhart, R. Roriz, P. Staat, D. Blanchard, Fabiani J. -N., A. Lafont, R. Zegdi, D. Heudes, P. Ohlmann, M. Kindo, Mazzucotelli J. -P., M. Zupan, G. Grollier, C. Ivascau, T. Lognone, Massimo Massetti, R. Sabatier, B. Huret, A. Gommeaux, P. Hochart, Pecheux, Claudel J. -P., D. Bouchayer, F. Gabrielle, F. Pelissier, G. Tremeau, F. Bourlon, G. Dreyfus, A. Eker, Y. Habib, N. Hugues, C. Mialhe, B. Bertrand, O. Chavanon, P. Porcu, G. Vanzetto

*Corresponding author

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background Transcatheter aortic valve replacement (TAVR) has revolutionized management of high-risk patients with severe aortic stenosis. However, survival and the incidence of severe complications have been assessed in relatively small populations and/or with limited follow-up. Objectives This report details late clinical outcome and its determinants in the FRANCE-2 (FRench Aortic National CoreValve and Edwards) registry. Methods The FRANCE-2 registry prospectively included all TAVRs performed in France. Follow-up was scheduled at 30 days, at 6 months, and annually from 1 to 5 years. Standardized VARC (Valve Academic Research Consortium) outcome definitions were used. Results A total of 4,201 patients were enrolled between January 2010 and January 2012 in 34 centers. Approaches were transarterial (transfemoral 73%, transapical 18%, subclavian 6%, and transaortic or transcarotid 3%) or, in 18% of patients, transapical. Median follow-up was 3.8 years. Vital status was available for 97.2% of patients at 3 years. The 3-year all-cause mortality was 42.0% and cardiovascular mortality was 17.5%. In a multivariate model, predictors of 3-year all-cause mortality were male sex (p < 0.001), low body mass index, (p < 0.001), atrial fibrillation (p < 0.001), dialysis (p < 0.001), New York Heart Association functional class III or IV (p < 0.001), higher logistic EuroSCORE (p < 0.001), transapical or subclavian approach (p < 0.001 for both vs. transfemoral approach), need for permanent pacemaker implantation (p = 0.02), and post-implant periprosthetic aortic regurgitation grade ≥2 of 4 (p < 0.001). Severe events according to VARC criteria occurred mainly during the first month and subsequently in <2% of patients/year. Mean gradient, valve area, and residual aortic regurgitation were stable during follow-up. Conclusions The FRANCE-2 registry represents the largest database available on late results of TAVR. Late mortality is largely related to noncardiac causes. Incidence rates of severe events are low after the first month. Valve performance remains stable over time.
Original languageEnglish
Pages (from-to)1637-1647
Number of pages11
JournalJournal of the American College of Cardiology
Volume68
Issue number15
DOIs
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Keywords

  • 80 and over
  • Aged
  • Aortic Valve Stenosis
  • Female
  • France
  • Humans
  • Male
  • Prospective Studies
  • Registries
  • Risk Assessment
  • Time Factors
  • Transcatheter Aortic Valve Replacement
  • Treatment Outcome
  • aortic stenosis
  • predictive analysis
  • risk score

Fingerprint

Dive into the research topics of 'Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 Registry'. Together they form a unique fingerprint.

Cite this